In a deal worth approximately $935 million, Jazz Pharmaceuticals will acquire the biopharmaceutical company Chimerix. Jazz will now own Chimerix’s leading drug, dordaviprone, a novel first-in-class ...

FGFR3 mutations and HER2 positivity in bladder cancer guide treatment with erdafitinib and fam-trastuzumab deruxtecan-nxki, respectively. Emerging biomarkers such as KIM-1 in renal cell carcinoma and ...

Tyra Biosciences' TYRA-300, an oral FGFR3 inhibitor, showed promising efficacy but raised concerns with some FGFR1/2-driven adverse events, causing a significant stock drop. TYRA-300 demonstrated ...

First — specifically in stage 4 disease — do I have a gene mutation? Do I have a gene mutation called FGFR3, because if you do, you can receive a medication called Balversa [erdafitinib]. [This agent] ...

LY3866288, an FGR3-specific inhibitor, led to an objective response in 42% of patients with metastatic urothelial carcinoma in a phase I study. The drug did not induce adverse events more commonly ...

In this video, Gopa Iyer, MD, shares the background and findings from the study, “A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in ...

This fundamental article significantly advances our understanding of FGF signalling, and in particular, highlights the complex modifications affecting this pathway. The evidence for the authors' ...

The FDA fully approved Balversa (erdafitinib) as a targeted therapy for metastatic bladder cancer with FGFR3 or FGFR2 genetic ...

11 xenograft mouse model, accompanied with inhibition of phospho-FGFR3, phospho-JAK2, phospho-STAT3 and Cyclin D2 levels. In sum, AZD1480 blocks proliferation, survival, FGFR3 and JAK/STAT3 ...